Advertisement

Reactions Weekly

, Volume 1710, Issue 1, pp 123–123 | Cite as

Docetaxel/ramucirumab

Various toxicities: 12 case reports
Case report
  • 23 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective study of 61 patients, 12 patients (8 men and 4 women) aged 63−79 years were described, who developed anaemia, thrombocytopenia, anorexia, mucositis, malaise, hand-foot syndrome, hypertension, interstitial lung disease or febrile neutropenia during treatment with docetaxel and ramucirumab for non-small cell lung cancer (NSCLC) [durations of treatments to reactions onsets and outcomes not stated].

A 63-year-old man with pretreated NSCLC, started receiving IV docetaxel 60 mg/m2 plus IV ramucirumab 10 mg/kg on day 1 every 3 weeks. Subsequently, he developed grade 4 febrile neutropenia, which was considered as haematological toxicity following docetaxel and ramucirumab therapy.

A 75-year-old man with pretreated NSCLC, started receiving IV docetaxel 60 mg/m2plus...

Reference

  1. Hata A, et al. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. Oncotarget 9: 27789-27796, No. 45, 12 Jun 2018. Available from: URL: http://doi.org/10.18632/oncotarget.25578- Japan

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations